Moderna, Inc. (NASDAQ:MRNA – Get Free Report) President Stephen Hoge sold 15,000 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the sale, the president now directly owns 1,486,241 shares in the company, valued at $156,085,029.82. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Stephen Hoge also recently made the following trade(s):
- On Thursday, February 29th, Stephen Hoge sold 2,388 shares of Moderna stock. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16.
Moderna Price Performance
NASDAQ MRNA opened at $102.00 on Friday. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $144.43. The stock has a market cap of $39.05 billion, a price-to-earnings ratio of -8.22 and a beta of 1.62. The company’s 50 day moving average is $100.35 and its two-hundred day moving average is $93.65. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on MRNA. Royal Bank of Canada reaffirmed an “outperform” rating and set a $125.00 price target on shares of Moderna in a report on Thursday, March 28th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday, April 11th. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target on the stock in a report on Tuesday, January 2nd. Finally, Canaccord Genuity Group raised their price target on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a report on Friday, February 23rd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $126.49.
View Our Latest Report on Moderna
Institutional Investors Weigh In On Moderna
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRNA. RB Capital Management LLC raised its stake in Moderna by 7.5% during the 1st quarter. RB Capital Management LLC now owns 2,267 shares of the company’s stock worth $391,000 after acquiring an additional 158 shares during the period. Synovus Financial Corp raised its position in shares of Moderna by 8.0% during the first quarter. Synovus Financial Corp now owns 4,049 shares of the company’s stock valued at $704,000 after buying an additional 300 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Moderna by 5.1% during the first quarter. Dimensional Fund Advisors LP now owns 987,478 shares of the company’s stock valued at $170,121,000 after buying an additional 47,755 shares during the last quarter. Blair William & Co. IL raised its position in shares of Moderna by 12.4% during the first quarter. Blair William & Co. IL now owns 15,611 shares of the company’s stock valued at $2,689,000 after buying an additional 1,724 shares during the last quarter. Finally, Sei Investments Co. raised its position in shares of Moderna by 41.4% during the first quarter. Sei Investments Co. now owns 58,160 shares of the company’s stock valued at $10,019,000 after buying an additional 17,031 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.
Moderna Company Profile
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Recommended Stories
- Five stocks we like better than Moderna
- 10 Best Airline Stocks to Buy
- Comprehensive PepsiCo Stock Analysis
- Most active stocks: Dollar volume vs share volume
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How to Most Effectively Use the MarketBeat Earnings Screener
- Bear Market Funds to Watch This Year
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.